Anixa Biosciences, Inc. (NASDAQ: ANIX) is one of the leading biotechnology company developing therapies and vaccines for cancer and other infectious diseases. Based on our Proof of Concept (POC) animal study results, we are working towards developing an orally administrable therapeutic that is a potentail antiviral therapy against the SARS-CoV-2.
Anixa and OntoChem, in collaboration, are developing an orally administrable therapeutic that is an antiviral therapy against the SARS-CoV-2, the virus responsible for Covid-19. Both the companies have recently completed POC studies in a Syrian Hamster model of the Covid-19 disease, two potential compounds that were evaluated, and Remdesivir. The collected data shows that the drugs infected the hamster and did not cause any other noticeable side effects. By checking and monitoring all the data on the animals, our research shows comparable efficacy of both Anixa compounds and Remdesivir. Other findings were inconclusive, perhaps due to the animal model being inadequate.
Dr Amit Kumar, President and CEO of Anixa Biosciences, stated, “Based on the promising preliminary data in the animal study, we have decided to proceed to the next stage of drug development. We have chosen one compound around which we will perform combinatorial synthetic, medicinal chemistry to evaluate whether we can increase potency and optimize pharmacokinetics. The most promising compounds will again be evaluated in both in vitro and in vivo studies.”
Insight into Anixa Biosciences, Inc.
Anixa Biosciences, Inc. is a publicly traded company biotechnology company developing several programs addressing cancer and infectious disease. We have developed immunotherapy against breast cancer and ovarian cancer. We are presently working towards creating an orally administrable therapeutic that is an antiviral therapy against the SARS-CoV-2. Our vaccination technologies focus on immunizing against specific proteins that are expressed in certain forms of cancer.
We always issue a forward-looking statement (statements that are not based on historic facts and are under the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statement expresses Anixa’s current expectations, future events and outcomes. Our most commonly used words are “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will”, and similar expressions to identify forward-looking statements. Our work involves risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.
As a publicly traded company, we take no obligation to update or revise any forward-looking statements publicly, except as required by law. As a reader, you are cautioned not to believe in such forward-looking statements when evaluating the information presented in this press release.
